Factors That Affect the Sensitivity of Imaging Modalities in Primary Hyperparathyroidism

Table 1

Clinical features and laboratory test results in PHPT patients.

	Total patients
Number	352
Age, y	53.4 ± 12.5
Sex (female : male)	2.96 : 1
Duration of disease, y	1 (0.2–4.0)
Nephrolithiasis (n, %)	136 (38.64%)
Fracture (n, %)	30 (8.52%)
Serum calcium, mmol/L	2.76 ± 0.31
Serum phosphate, mmol/L	0.88 ± 0.20
Serum albumin, g/L	38.25 ± 3.72
Albumin-corrected serum calcium, mmol/L	2.79 ± 0.32
Serum PTH, pg/mL	247.3 (150.0–537.9)
Serum ALP, IU/L	93 (68–142)
Serum 25(OH)D, nmol/L	27.24 (18.05–38.68)
24 h urinary calcium, mmol/24 h	6.03 (4.35–8.09)
Serum creatinine, μmol/L	63 (54–79)
MDRD, ml/min/1.73 m^2	99 (80–113)
BMD L1-L4, g/cm^2	0.93 ± 0.20
T-score L1-L4	−1.58 ± 1.65
BMD femoral neck, g/cm^2	0.76 ± 0.14
T-score femoral neck	−1.30 ± 1.16
Osteoporosis (T ≦ −2.5) (%)	36.27%
Negative imaging results (n, %)	18 (5.11%)
Tumor length (cm)	1.8 (1.3–2.7)

PTH: parathyroid hormone; ALP: alkaline phosphatase; 25(OH)D: 25-hydroxyvitamin D; MDRD: modification of diet in renal disease; BMD: bone mineral density.